281 related articles for article (PubMed ID: 35339647)
1. Alternative RNA splicing defects in pediatric cancers: new insights in tumorigenesis and potential therapeutic vulnerabilities.
Venkataramany AS; Schieffer KM; Lee K; Cottrell CE; Wang PY; Mardis ER; Cripe TP; Chandler DS
Ann Oncol; 2022 Jun; 33(6):578-592. PubMed ID: 35339647
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers.
Sahin I; George A; Seyhan AA
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769221
[TBL] [Abstract][Full Text] [Related]
3. Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.
Urbanski LM; Leclair N; Anczuków O
Wiley Interdiscip Rev RNA; 2018 Jul; 9(4):e1476. PubMed ID: 29693319
[TBL] [Abstract][Full Text] [Related]
4. Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance.
Roy Burman D; Das S; Das C; Bhattacharya R
Mol Biol Rep; 2021 Jan; 48(1):897-914. PubMed ID: 33400075
[TBL] [Abstract][Full Text] [Related]
5. Cancer-Associated Perturbations in Alternative Pre-messenger RNA Splicing.
Shkreta L; Bell B; Revil T; Venables JP; Prinos P; Elela SA; Chabot B
Cancer Treat Res; 2013; 158():41-94. PubMed ID: 24222354
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the c.793-1G > A splicing variant in CHEK2 gene as pathogenic: a case report.
Agiannitopoulos K; Papadopoulou E; Tsaousis GN; Pepe G; Kampouri S; Kocdor MA; Nasioulas G
BMC Med Genet; 2019 Jul; 20(1):131. PubMed ID: 31349801
[TBL] [Abstract][Full Text] [Related]
7. Alternative Splicing: Expanding the Landscape of Cancer Biomarkers and Therapeutics.
Bessa C; Matos P; Jordan P; Gonçalves V
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261131
[TBL] [Abstract][Full Text] [Related]
8. RNA splicing dysregulation and the hallmarks of cancer.
Bradley RK; Anczuków O
Nat Rev Cancer; 2023 Mar; 23(3):135-155. PubMed ID: 36627445
[TBL] [Abstract][Full Text] [Related]
9. Alternative RNA Splicing-The Trojan Horse of Cancer Cells in Chemotherapy.
Mehterov N; Kazakova M; Sbirkov Y; Vladimirov B; Belev N; Yaneva G; Todorova K; Hayrabedyan S; Sarafian V
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356101
[TBL] [Abstract][Full Text] [Related]
10. Exon-level transcriptome profiling in murine breast cancer reveals splicing changes specific to tumors with different metastatic abilities.
Bemmo A; Dias C; Rose AA; Russo C; Siegel P; Majewski J
PLoS One; 2010 Aug; 5(8):e11981. PubMed ID: 20700505
[TBL] [Abstract][Full Text] [Related]
11. Modification of alternative splicing by antisense oligonucleotides as a potential chemotherapy for cancer and other diseases.
Mercatante DR; Sazani P; Kole R
Curr Cancer Drug Targets; 2001 Nov; 1(3):211-30. PubMed ID: 12188880
[TBL] [Abstract][Full Text] [Related]
12. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
[TBL] [Abstract][Full Text] [Related]
13. RNA Splicing and Cancer.
Wang E; Aifantis I
Trends Cancer; 2020 Aug; 6(8):631-644. PubMed ID: 32434734
[TBL] [Abstract][Full Text] [Related]
14. Entropy measures quantify global splicing disorders in cancer.
Ritchie W; Granjeaud S; Puthier D; Gautheret D
PLoS Comput Biol; 2008 Mar; 4(3):e1000011. PubMed ID: 18369415
[TBL] [Abstract][Full Text] [Related]
15. RNA splicing: a dual-edged sword for hepatocellular carcinoma.
Kashyap A; Tripathi G; Tripathi A; Rao R; Kashyap M; Bhat A; Kumar D; Rajhans A; Kumar P; Chandrashekar DS; Mahmood R; Husain A; Zayed H; Bharti AC; Kashyap MK
Med Oncol; 2022 Aug; 39(11):173. PubMed ID: 35972700
[TBL] [Abstract][Full Text] [Related]
16. Long Non-Coding RNA Expression Levels Modulate Cell-Type-Specific Splicing Patterns by Altering Their Interaction Landscape with RNA-Binding Proteins.
Porto FW; Daulatabad SV; Janga SC
Genes (Basel); 2019 Aug; 10(8):. PubMed ID: 31390792
[TBL] [Abstract][Full Text] [Related]
17. LOX-1 and Its Splice Variants: A New Challenge for Atherosclerosis and Cancer-Targeted Therapies.
Rizzacasa B; Morini E; Pucci S; Murdocca M; Novelli G; Amati F
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146073
[TBL] [Abstract][Full Text] [Related]
18. Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival.
Renshaw J; Orr RM; Walton MI; Te Poele R; Williams RD; Wancewicz EV; Monia BP; Workman P; Pritchard-Jones K
Mol Cancer Ther; 2004 Nov; 3(11):1467-84. PubMed ID: 15542786
[TBL] [Abstract][Full Text] [Related]
19. Splice variants of MDM2 in oncogenesis.
Rosso M; Okoro DE; Bargonetti J
Subcell Biochem; 2014; 85():247-61. PubMed ID: 25201199
[TBL] [Abstract][Full Text] [Related]
20. Alternative splicing: a new breakthrough for understanding tumorigenesis and potential clinical applications.
Park J; Park J; Chung YJ
Genes Genomics; 2023 Apr; 45(4):393-400. PubMed ID: 36656436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
